Slamon等[1]于1987年提出表皮生长因子受体-2(cerbB-2)是乳腺癌术后早期复发和预后差的分子标志物。国外的大多数研究支持此结论[2]。但国内研究样本大多少于200例和/或随访时间小于5年[3],在评价cerbB-2表达在中国妇女乳腺癌预后中的作用时存在一定局限性。本文采用有长期随访 Slamon et al [1] in 1987 proposed that epidermal growth factor receptor-2 (cerbB-2) is a molecular marker of early postoperative recurrence and poor prognosis of breast cancer. Most foreign studies support this conclusion [2]. However, most of the domestic studies have less than 200 samples and / or follow-up times less than 5 years [3]. There are some limitations in evaluating the role of cerbB-2 in the prognosis of breast cancer in Chinese women. This article uses a long-term follow-up